Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
abeyance, adherence, adjourned, adjournment, admission, Africa, algorithm, alleviate, allodynic, Alora, alpha, amoubt, amplitude, apptec, Arab, arousal, attrition, Barry, belief, bioanalytic, Biotherapeutic, bradycardia, broader, burst, capsaicin, CDMO, clawback, closure, commercializng, conference, conservation, contemporary, convened, cybersecurity, deep, demographic, density, diligence, disaster, dissolution, divestiture, emulate, escalate, expiry, fashion, FIH, foot, forearm, formal, Frey, frontal, gamma, goodwill, greedy, hair, headcount, hearing, heat, inhibitory, learning, left, leveraged, lockout, MEP, Mexico, middle, morale, neurotransmission, Nowithstanding, PainCart, parietal, path, phishing, PR, prepay, prolongation, prone, propensity, quorum, realignment, recoded, reconvene, regular, remedial, remediate, rescission, resting, RMT, running, Russia, scoring, sensation, sex, skin, sleep, spectral, speculation, tabletop, theta, timepoint, timetable, toxicology, triage, undertaken, underwent, unexposed, unregistered, upper, upward, vendor, video, Von, winding, wuxi
Removed:
abbvie, abdominoplasty, acelrx, Aimovig, Ajovy, Alder, Allergan, Amgen, ANJESO, antibody, APOLLO, arrestin, ASU, ATHENA, attending, avoided, Baudax, biohaven, BMI, Botox, bunionectomy, burden, button, capsule, categorical, CGRP, cohort, colorectal, Colucid, comorbid, conditional, coupling, crystalline, deplete, deploying, derived, desire, disadvantage, discontinued, DOR, durect, economy, educate, efficiency, elderly, electroencephalography, elevated, Eli, emerge, emergence, Emgality, encompassed, erenumab, ergot, ethical, faced, fasted, fed, fluid, focusing, framing, fremanezumab, galcanezumab, gold, gynecologic, half, headache, heightened, hindered, hired, hypoxia, incidence, indefinite, index, inpatient, intensity, interrupt, investigator, knockout, Lasmiditan, leading, lesser, Mallinckrodt, mandated, mice, migraine, minimize, movement, multicenter, multiplicity, NSAID, numerical, NURTEC, obese, offered, OFIRMEV, older, opt, orthopedic, outsource, oxygen, Parallax, peptide, pivotal, potent, preceding, predicted, prematurely, preventative, prioritization, proceed, prophylactic, propranolol, quarantine, rating, regimen, reposition, representative, rescue, responder, REYVOW, Rimegepant, saturation, selective, selectively, SPID, spontaneously, spread, standardized, strain, suffering, suggest, sum, superior, telemedicine, Teva, tolerate, topiramate, triptan, Ubrelvy, ubrogepant, underinsured, uninsured, unique, unnecessarily, validation, vital, volunteer, VyeptiTM, worsening, ZALVISO, zavegepant
Filing tables
Filing exhibits
Related press release
TRVN similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
1) | Registration Statement (Form S-8 No. 333-273294) pertaining to the Trevena, Inc. 2023 Equity Incentive Plan, |
2) | Registration Statement (Form S-8 No. 333-215420) pertaining to the Trevena, Inc. Inducement Plan, |
3) | Registration Statement (Form S-3 No. 333-275866) of Trevena, Inc., and |
4) | Registration Statement (Form S-3 No. 333-276458) of Trevena, Inc. |
of our report dated April 1, 2024, with respect to the financial statements of Trevena, Inc. included in this Annual Report (Form 10-K) of Trevena, Inc. for the year ended December 31, 2023.
/s/ Ernst & Young LLP
Philadelphia, Pennsylvania
April 1, 2024